PM8002 + pemetrexed + cisplatin

PM8002 + pemetrexed + cisplatin is a combination therapy under investigation for oncology indications. **PM8002** is a bispecific monoclonal antibody targeting PD-L1 (programmed death-ligand 1) and VEGF (vascular endothelial growth factor), designed to modulate immune response and inhibit tumor angiogenesis[3][5]. **Pemetrexed** is a small molecule antineoplastic agent, specifically an antifolate that inhibits multiple folate-dependent enzymes essential for purine and pyrimidine synthesis, mainly used in the treatment of non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma[1][2][4][6]. **Cisplatin** is a platinum-based small molecule chemotherapy that forms DNA crosslinks, inhibiting DNA replication and causing cell death[1][2][4][6]. This combination is being evaluated as a first-line regimen for conditions like malignant pleural mesothelioma (MPM) and NSCLC, offering potential synergistic anti-tumor activity by combining immunotherapy, anti-angiogenesis, and cytotoxic mechanisms[3][5].

Other names

PM8002 + pemetrexed + cisplatinPM8002 (Anti-PD-L1/VEGF) + pemetrexed + cisplatin